Magnisense

About Magnisense

Magnisense, now operating as Ovvi Diagnostics, is a medical technology firm focused on developing point-of-care diagnostic solutions. Initially founded in Paris, France, in 2003 by Ingmar Adlerberg, the company pioneered emergency diagnostic tests for cardiovascular diseases. One report indicates the company was formed in 2008 based on an invention by Russian physicist Petr Nikitin. The company's core technology, known as MIAtek®, utilizes magnetic nanoparticles for rapid and sensitive assays. This proprietary technology, protected by worldwide patents, allows for the quantitative measurement of biomarkers directly from whole blood in approximately 15 minutes.

Historically, Magnisense concentrated on the cardiovascular sector, developing a portable, battery-powered device capable of performing multiple tests in parallel. The company achieved CE marking in Europe for its acute heart failure (Miag|bnp) test in 2017 and a myocardial infarction (Miag|cTnl) test in 2018. These tests were designed for use by emergency physicians, cardiologists, and biologists in critical situations where rapid diagnosis is vital. The business model involved selling these mobile devices and related consumables to hospitals, clinics, and emergency services. Over the years, Magnisense secured significant funding, including a €5.5 million round in 2015 and a €5 million Series A in 2018, to support product development and commercial expansion in Europe.

In July 2020, Magnisense was acquired by and rebranded as Ovvi Diagnostics, a Belgian-based startup founded in the same year. This strategic shift pivoted the company's focus exclusively to women's health. Leveraging the foundational MIAtek® technology, Ovvi Diagnostics is developing a point-of-care testing system for concerns such as infertility and post-partum hemorrhage. The product lineup is expanding to include saliva-based tests for infectious diseases like COVID-19 and Flu, developed in collaboration with the NIH's RADx program to be accessible for users with physical limitations. The current strategy targets both professional use by OB/GYNs and at-home self-testing, with results transmitted automatically to physicians, aiming to address women's diagnostic needs throughout their lives.